These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27047745)

  • 1. The 2.2-Angstrom resolution crystal structure of the carboxy-terminal region of ataxin-3.
    Zhemkov VA; Kulminskaya AA; Bezprozvanny IB; Kim M
    FEBS Open Bio; 2016 Mar; 6(3):168-78. PubMed ID: 27047745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coiled-coil structure-dependent interactions between polyQ proteins and Foxo lead to dendrite pathology and behavioral defects.
    Kwon MJ; Han MH; Bagley JA; Hyeon DY; Ko BS; Lee YM; Cha IJ; Kim SY; Kim DY; Kim HM; Hwang D; Lee SB; Jan YN
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10748-E10757. PubMed ID: 30348793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and dynamic studies reveal that the Ala-rich region of ataxin-7 initiates α-helix formation of the polyQ tract but suppresses its aggregation.
    Hong JY; Wang DD; Xue W; Yue HW; Yang H; Jiang LL; Wang WN; Hu HY
    Sci Rep; 2019 May; 9(1):7481. PubMed ID: 31097749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine tracts regulate autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Autophagy; 2017 Sep; 13(9):1613-1614. PubMed ID: 28722507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ataxin-2 mediated cell death is dependent on domains downstream of the polyQ repeat.
    Ng H; Pulst SM; Huynh DP
    Exp Neurol; 2007 Dec; 208(2):207-15. PubMed ID: 17949716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary structures of native and pathogenic huntingtin N-terminal fragments.
    Długosz M; Trylska J
    J Phys Chem B; 2011 Oct; 115(40):11597-608. PubMed ID: 21910495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
    Cummings CJ; Orr HT; Zoghbi HY
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference of Crx-dependent transcription by ataxin-7 involves interaction between the glutamine regions and requires the ataxin-7 carboxy-terminal region for nuclear localization.
    Chen S; Peng GH; Wang X; Smith AC; Grote SK; Sopher BL; La Spada AR
    Hum Mol Genet; 2004 Jan; 13(1):53-67. PubMed ID: 14613968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyglutamine Tract Expansion Increases S-Nitrosylation of Huntingtin and Ataxin-1.
    Ni CL; Seth D; Fonseca FV; Wang L; Xiao TS; Gruber P; Sy MS; Stamler JS; Tartakoff AM
    PLoS One; 2016; 11(9):e0163359. PubMed ID: 27658206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3.
    Masino L; Nicastro G; Menon RP; Dal Piaz F; Calder L; Pastore A
    J Mol Biol; 2004 Dec; 344(4):1021-35. PubMed ID: 15544810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
    Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
    J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
    Matos CA; de Macedo-Ribeiro S; Carvalho AL
    Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites.
    Kristensen LV; Oppermann FS; Rauen MJ; Hartmann-Petersen R; Thirstrup K
    Neurochem Int; 2017 May; 105():42-50. PubMed ID: 28065793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a recruitment and sequestration mechanism in Huntington's disease.
    Preisinger E; Jordan BM; Kazantsev A; Housman D
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1029-34. PubMed ID: 10434302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 5 phosphorylates and induces the degradation of ataxin-2.
    Asada A; Yamazaki R; Kino Y; Saito T; Kimura T; Miyake M; Hasegawa M; Nukina N; Hisanaga S
    Neurosci Lett; 2014 Mar; 563():112-7. PubMed ID: 24486837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association with proteasome determines pathogenic threshold of polyglutamine expansion diseases.
    Kim M; Bezprozvanny I
    Biochem Biophys Res Commun; 2021 Jan; 536():95-99. PubMed ID: 33370719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils.
    Bevivino AE; Loll PJ
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):11955-60. PubMed ID: 11572942
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.